Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 1

Conditions

Primary Myelofibrosis 1Myelodysplastic-Myeloproliferative Diseases 1Immune Checkpoint Inhibitors (ICI)-Related Dermatitis 1

Interventions

Cyclophosphamide 2042Radiotherapy 1859Cisplatin 1825Carboplatin 1533Gemcitabine 1434Paclitaxel 1289Bevacizumab 1270Docetaxel 1202pembrolizumab 1199Oxaliplatin 1160Capecitabine 1144Fluorouracil 1061Dexamethasone 971Rituximab 919Nivolumab 908Magnetic Resonance Spectroscopy 862Etoposide 839Doxorubicin 823Drug Therapy 792Radiosurgery 776Irinotecan 775Cytarabine 736fludarabine 716Leucovorin 676Lenalidomide 608fludarabine phosphate 564Temozolomide 552Radiation 541Filgrastim 540Cetuximab 537

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Interventional × Janus Kinase Inhibitors × Clear all
NCT07228624 2026-02-19

Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes

Fred Hutchinson Cancer Center

Phase 2 Recruiting
50 enrolled
Myeloid

Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT06715982 2025-10-28

JAK Inhibitors for Solid Malignant Tumor Patients With Immune Checkpoint Inhibitors-related Dermatitis: A Open-lable, Single Arm, Phase IIa Trial

Hangzhou Cancer Hospital

Phase 2 Recruiting
35 enrolled

Immune Checkpoint Inhibitors (ICI)-Related Dermatitis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡